Clinical Trials · NCT02333370

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Name: A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1Gonadorelin

Phase: Phase 1
Recruitment status: Completed
Sponsor: Novartis Pharmaceuticals
Enrollment: 88
Start date: Feb 2015
Locations: 15 sites, 3 countries
Primary endpoint: Phase Ib Dose escalation - Frequency of dose limiting toxicities (DLTs)

View Gonadorelin compound reference